Victory Capital Management Inc. Purchases 464 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Victory Capital Management Inc. raised its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 11.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,569 shares of the company’s stock after purchasing an additional 464 shares during the period. Victory Capital Management Inc.’s holdings in TransMedics Group were worth $717,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Amalgamated Bank increased its position in shares of TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares during the last quarter. Harbour Capital Advisors LLC grew its stake in TransMedics Group by 1.7% in the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after buying an additional 81 shares in the last quarter. Signaturefd LLC increased its holdings in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the last quarter. Arizona State Retirement System raised its position in shares of TransMedics Group by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after buying an additional 186 shares in the last quarter. Finally, Venturi Wealth Management LLC lifted its holdings in shares of TransMedics Group by 33.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after acquiring an additional 219 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. The trade was a 12.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,958 shares of company stock valued at $3,470,328 over the last ninety days. 7.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. reduced their target price on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 29th. Stephens increased their price objective on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Needham & Company LLC restated a “hold” rating and issued a $109.00 target price on shares of TransMedics Group in a research report on Friday, November 22nd. TD Cowen cut their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Finally, Oppenheimer decreased their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $87.11 on Friday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a fifty-two week low of $67.77 and a fifty-two week high of $177.37. The firm has a market cap of $2.92 billion, a PE ratio of 92.67 and a beta of 2.08. The business has a 50 day moving average price of $113.26 and a 200-day moving average price of $136.45.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the previous year, the company earned ($0.12) EPS. The company’s quarterly revenue was up 63.7% on a year-over-year basis. Equities research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.